TickerTalks
Browse all tickers →
TickerTalks›$GPCR
GPGPCR

Structure Therapeutics Inc.

$GPCR·$3.1B·Biotechnology·Healthcare
$45.91-3.1%YTD-28.9%1Y+128.6%
Mentions · last 7 days
2026-08-22: 3 posts2026-08-23: 6 posts2026-08-24: 5 posts31+8%
Price updated 7h ago·X counts updated 7d ago
GPGPCR
$GPCRStructure Therapeutics Inc.
$45.91-3.08%31 posts+8%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $GPCR, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-08-20

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Structure Therapeutics oral GLP-1 developer +188% TTM — GSBR-1290 obesity Phase 2/3 data is the entire investment case.

Structure Therapeutics is a clinical-stage biopharma developing oral small-molecule therapies for chronic diseases — with GSBR-1290 (an oral GLP-1) as the flagship obesity/diabetes candidate, positioned to compete with LLY/NVO injectables and Viking's oral candidate.

Where it stands:

  • The revenue is zero: no operational business, and Q1 EPS of -$1.05 vs -$0.85 estimate — this is a pure clinical-development option.
  • The valuation is entirely narrative-driven: -20x trailing PE with meaningful cash burn — the market cap of $3.06B is pricing high probability of positive obesity trial outcomes.
  • The recent Cantor and Piper Sandler Overweight reiterations on Viking (peer set) validate the broader oral-GLP-1 thesis — Structure is directly comparable.
  • The insider tape has small A-Award grants plus minor sales — no major directional signal.
  • Position at 47% of 52-week range and +9% above the 50-day means the tape is coiling after the +188% TTM run.
  • The 10%+ beneficial owner Form 3 (Aug 7) adds an institutional-holder overhang that's worth watching.

The operative catalysts are GSBR-1290 Phase 2/3 data readouts and any partnership announcements with big pharma. Positive Phase 3 obesity data with clean tolerability profile could 2x the tape toward $100; a negative readout or a competitive Viking readout is what tests $35.

Agrees with X sentimentX's read on Structure as the next-leg-higher obesity/GLP-1 play alongside Viking (peer validated by Cantor/Piper Sandler) is grounded — the retail 'run toward $100 or buyout' framing is aspirational but not unreasonable given the TAM.

What to watch: Any GSBR-1290 Phase 2/3 data readouts, big-pharma partnership announcements, and Viking peer data. Positive data + partnership 2x toward $100; negative data or Viking miss tests $35.

On the calendar: 2026-11-05 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-07-08

Structure Therapeutics is being framed as a next-leg-higher obesity/GLP-1 play. Cantor and Piper Sandler both reiterated Overweight on Viking Therapeutics with GPCR named in the same peer set alongside LLY and NVO, and a Chinese small-molecule GLP-1 competitor is being cross-analyzed as validation of the space rather than a direct threat. Retail voices are more emphatic, calling for a run toward $100 or a buyout given repeated tests of overhead resistance on light volume, though the sample is thin.

Read the AI verdict + X sentiment for $GPCR

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing an oral GLP-1 receptor agonist (GSBR-1290) for obesity and type 2 diabetes, with additional GPCR pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $GPCR.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $GPCR

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+48.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-19.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-14.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-5.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-15.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.49$-0.39-25.6%
Q1 2026May 7, 2026$-0.35$-0.39+10.3%
Q4 2025Feb 26, 2026$-0.49$-0.35-40.0%
Q3 2025Nov 6, 2025$-0.37$-0.36-2.8%
Next earningsThu, Nov 5·consensus EPS $-0.32

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-1.05$14.1M
Q4 FY25$0———$0.60$-65.9M
Q3 FY25$0———$-1.11$-52.6M
Q2 FY25$0———$-1.08$-54.8M

Forward consensus

5-year forecast · up to 12 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$41.7M$41.7M – $41.7M-$1.43-$1.69 – -$1.269
FY27$56K$56K – $56K-$1.98-$2.52 – -$1.7112
FY28$213.0M$213.0M – $213.0M-$1.54-$2.33 – $1.0510
FY29$539.4M$539.4M – $539.4M-$0.29-$0.29 – -$0.295
FY30$831.6M$831.6M – $831.6M$1.07$1.07 – $1.075

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.2.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.36%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-9.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-15.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 54.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-1.515-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 18Xichen LinCHIEF SCIENTIFIC OFFICER3.9K sh—SellAug 4Xichen LinCHIEF SCIENTIFIC OFFICER3.9K sh—SellJul 22Llc FmrSee Remark 117.5K sh—SellJul 14Xichen LinCHIEF SCIENTIFIC OFFICER7.9K sh—SellJun 25Xichen LinCHIEF SCIENTIFIC OFFICER7.9K sh—SellApr 14Llc FmrSee Remark 117.5K sh—
+ 22 other (14 awards · 4 exempts · 4 conversions) in window

See when $GPCR insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsAug 73
AI summary

A new 10%+ beneficial owner filed a Form 3 initial statement of ownership for GPCR (GPCR) dated 2026-08-07. The filing reports initial beneficial ownership of shares, representing approximately a 10%+ stake of outstanding shares. Form 3 is required within 10 days of crossing the 10% ownership threshold and is an administrative disclosure. This indicates significant insider or institutional accumulation and may precede further Schedule 13D/G activity.

8-KShareholder voteJun 188-K — Item 5.07: Shareholder vote
8-KMaterial agreementMay 78-K — Item 1.01: Material agreement · Item 2.02: Earnings release · Item 8.01: Other event
424B5Prospectus supplement (offering)May 7424B5
AI summary

Structure Therapeutics amended and restated its ATM sales agreement removing the aggregate offering cap, and filed this 424B5 to increase the maximum ATM capacity to $400M aggregate gross; approximately $58.5M (3.04M ADSs) had been sold under the prior agreement, leaving approximately $341.5M remaining capacity. Major ATM upsizing to $400M total; $341.5M remaining represents substantial ongoing dilution potential.

3New insider — initial holdingsApr 233
8-KOfficer or director changeApr 158-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
8-KPress release / Reg FDMar 168-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
+ 6 other (2 10-Qs · 1 earnings 8-K · 1 13G · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Termseekingalpha.com·3d agoNVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?zacks.com·6d agoStructure Therapeutics: A Strong Bet For An Oral GLP-1 Approval Before 2030seekingalpha.com·11d agoLLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?zacks.com·15d agoAbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profigurufocus.com·22d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · top 3 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport